Evaluation of protective effects of GnRH agonist or antagonist on ovarian reserve with anti-Müllerian hormone and histological analysis in a rat model using cisplatin

ArticleAçık Erişim

Özet

Introduction: The aim of this prospective trial was to evaluate the ovarian reserve with anti-Müllerian hormone (AMH), which is the best predictor of ovarian reserve, and perform histological analysis after exposure to cisplatin with a GnRH agonist or antagonist. Material and methods: Twenty-four Wistar albino rats were randomly divided into three groups, each consisting of eight rats. In the GnRH agonist group (group 1), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg triptorelin. In the GnRH antagonist group (group 2), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg cetrorelix. In the control group (group 3), rats received 50 mg/m2 cisplatin. Ovarian reserve was assessed by AMH and histology. Results: Primary follicle counts were higher in group 2 (4.50 ±1.47 vs. 3.50 ±1.70 vs. 3.00 ±3.54) and secondary follicle counts were higher in group 1 (2.96 ±1.11 vs. 1.74 ±1.03 vs. 1.37 ±3.11). Numbers of tertiary follicles were higher both in groups 1 and 2 than the control group (1.36 ±0.83 vs. 0.84 ±0.99 vs. 0.50 ±0.75). The total follicle count of the study groups were significantly higher compared with the control group (14.32 ±5.96 vs. 12.48 ±4.12 vs. 10.63 ±6.80). AMH was significantly higher in groups 1 and 2 compared with the control group (18.56 ±25.33 vs. 16.48 ±24.66 vs. 9.37 ±26.54). Conclusions: This is the first prospective randomized controlled study showing the protective effects of GnRH agonist and antagonist on ovarian reserve after cisplatin exposure in an animal model. Copyright © 2019 Termedia & Banach.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12225Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.5114/aoms.2019.87540Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorTas, Mustafa
dc.contributor.authorOner, Gokalp
dc.contributor.authorUlug, Pasa
dc.contributor.authorYavuz, Adem
dc.contributor.authorOzcelik, Bulent
dc.date.accessioned2026-10-18T20:27:09.068625563Z
dc.date.available2026-10-18T20:27:09.068625563Z
dc.date.issued2023
dc.description.abstractIntroduction: The aim of this prospective trial was to evaluate the ovarian reserve with anti-Müllerian hormone (AMH), which is the best predictor of ovarian reserve, and perform histological analysis after exposure to cisplatin with a GnRH agonist or antagonist. Material and methods: Twenty-four Wistar albino rats were randomly divided into three groups, each consisting of eight rats. In the GnRH agonist group (group 1), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg triptorelin. In the GnRH antagonist group (group 2), rats received a single dose of 50 mg/m2 cisplatin with 1 mg/kg cetrorelix. In the control group (group 3), rats received 50 mg/m2 cisplatin. Ovarian reserve was assessed by AMH and histology. Results: Primary follicle counts were higher in group 2 (4.50 ±1.47 vs. 3.50 ±1.70 vs. 3.00 ±3.54) and secondary follicle counts were higher in group 1 (2.96 ±1.11 vs. 1.74 ±1.03 vs. 1.37 ±3.11). Numbers of tertiary follicles were higher both in groups 1 and 2 than the control group (1.36 ±0.83 vs. 0.84 ±0.99 vs. 0.50 ±0.75). The total follicle count of the study groups were significantly higher compared with the control group (14.32 ±5.96 vs. 12.48 ±4.12 vs. 10.63 ±6.80). AMH was significantly higher in groups 1 and 2 compared with the control group (18.56 ±25.33 vs. 16.48 ±24.66 vs. 9.37 ±26.54). Conclusions: This is the first prospective randomized controlled study showing the protective effects of GnRH agonist and antagonist on ovarian reserve after cisplatin exposure in an animal model. Copyright © 2019 Termedia & Banach.
dc.identifier.doi10.5114/aoms.2019.87540
dc.identifier.eissn1896-9151
dc.identifier.endpage451
dc.identifier.issn1734-1922
dc.identifier.issue2
dc.identifier.pmcidPMC10074176
dc.identifier.pmid37034528
dc.identifier.scopus2-s2.0-85152171477
dc.identifier.startpage448
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12225
dc.identifier.volume19
dc.identifier.wosWOS:000980693500019
dc.language.isoen
dc.publisherTermedia Publishing House Ltd.
dc.relation.ispartofArchives of Medical Science
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectanti-Müllerian hormone
dc.subjectcisplatin
dc.subjectovarian reserve
dc.subjectcetrorelix
dc.subjectMuellerian inhibiting factor
dc.subjecttriptorelin
dc.subjectanimal cell
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectantral follicle count
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectenzyme linked immunosorbent assay
dc.subjectevaluation study
dc.subjectfemale
dc.subjecthistology
dc.subjectnonhuman
dc.subjectprimordial follicle
dc.subjectprophylaxis
dc.subjectprospective study
dc.subjectrat
dc.subjectsingle drug dose
dc.subjectWistar rat
dc.titleEvaluation of protective effects of GnRH agonist or antagonist on ovarian reserve with anti-Müllerian hormone and histological analysis in a rat model using cisplatin
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus7
rdl.citation.wos7
rdl.departmentDepartment of Obstetrics and Gynecology, Erzincan University, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)